A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Amolimogene (ZYC101a) in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN 2/3) of the Uterine Cervix.

Trial Profile

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Amolimogene (ZYC101a) in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN 2/3) of the Uterine Cervix.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 29 May 2012

At a glance

  • Drugs Amolimogene bepiplasmid (Primary)
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jul 2011 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
    • 07 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Eisai Inc added as trial sponsor, affiliate and lead trial center as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top